

Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

Hope S. Rugo¹, Robert W. Sliemers², Hye Han³, Jennifer M. Specht⁴, E. Claire Desh⁵, Erica M. Stringer-Basson⁶, Peter Kabis⁷, Vandana Abramson⁸, Amy Weiss⁹, Anne Schott¹⁰, Marya Abu-Khalaf¹¹, Keerthi Gogineni¹², Alexander Spira¹³, Charlotte Moser¹⁴, Nadene Zack¹⁵, Samuel Suzuki¹⁶, Sarah Mukda¹⁷, Brian Sullivan¹⁸, Igor Gorbachevsky¹⁹, Rachel M. Layman²⁰

¹City of Hope Comprehensive Cancer Center, Duarte, CA; ²The Ohio State University Comprehensive Cancer Center, Columbus, OH; ³Moffitt Cancer Center, Tampa, FL; ⁴Fred Hutchinson Cancer Center, University of Washington, Seattle, WA; ⁵University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; ⁶Ohio State Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; ⁷University of Colorado Hospital, Aurora, CO; ⁸Novartis Oncology Medical Center, Nashville, TN; ⁹Novartis Oncology, Detroit, MI; ¹⁰University of Michigan, Ann Arbor, MI; ¹¹Thomas Jefferson University, Philadelphia, PA; ¹²Emory University Hospital, Atlanta, GA; ¹³Virginia Cancer Specialists, Fairfax, VA; ¹⁴Calcutta, Maryland, MD; ¹⁵The University of Texas MD Anderson Cancer Center, Houston, TX

Presented at
NCODA's 2025 Fall Summit


Previously presented at the
2024 San Antonio
Breast Cancer Symposium

BACKGROUND

- The estrogen receptor (ER), CDK4/6, and PI3K/AKT/mTOR (PAM) pathways each promote tumor cell proliferation in HR+, HER2-advanced breast cancer [ABC]. [1,2]
- This led to the approval of therapeutic regimens that include various combinations of endocrine therapies (ET), CDK4/6 inhibitors (CDK4/6i) and PAM inhibitors that target a single node of the PI3K/AKT/mTOR pathway for patients with HR+, HER2- ABC. [3-7]
- There is thus a strong scientific rationale to simultaneously blockade the ET, CDK4/6, and PAM pathways in both the first and second line setting to optimize anti-tumor control.
- To evaluate this hypothesis, a Phase Ib study (32551009) of gedatolisib, a PAM (pan-PI3K and mTORC1/2) inhibitor, palbociclib, a CDK4/6 inhibitor, and ET (letrozole or fulvestrant) in women with HR+/HER2- ABC was conducted. [8]
- In this analysis, we report overall survival data for two patient subgroups evaluated in the 32551009 study:
 - Patients who had prior treatment with a CDK4/6i and fulvestrant and received gedatolisib using the intermittent schedule being studied in an ongoing Phase 3 clinical trial (VICTORIA-3, NCT05501886).
 - Patients who were treatment-naïve in the metastatic setting and were eligible for treatment with a CDK4/6i and letrozole.
- As previously reported, ORR and mPFS for both subgroups of patients compare favorably to published data for current standard of care regimens. Additionally, as previously reported, responses were observed in patients regardless of PIKCA mutation status and few patients (<2%) discontinued treatment due to an adverse event [8,9].

Figure 1. The ER, CDK4/6, and PAM Pathways Are Interdependent Drivers of HR+/HER2- ABC

Dysregulation of these pathways promotes excessive cell proliferation and resistance to apoptosis



STUDY DESIGN



- Dosing information: Palbociclib: 125 mg/day in a 3 week on, 1 week off schedule; Letrozole: 2.5 mg/day; Fulvestrant: 500 mg intramuscular injection on cycle 1 days 1 and 15, and every 28 days ± 3 days thereafter; Gedatolisib: 180 mg IV weekly or three weeks on/one week off.
- Tumor assessment performed at baseline and every 8 weeks for at least the first 18 months of treatment until disease progression or the start of a new anti-cancer therapy.
- Endpoints: Primary – objective response per RECIST v1.1 assessed by the investigator; Secondary – safety, duration of response (DOR), and PFS.

Table 1: Baseline Characteristics

Parameters	1L Line Treatment-Naïve (N=41)	2L/3L CDK4/6i-Treated (N=27)
Age, years		
Median (range)	54 (28–78)	56 (34–79)
Prior Therapies – Advanced Breast Cancer, n (%)		
Prior Chemotherapy	NA	5 (19)
Prior SERD or SERM Therapy	NA	10 (37)
Prior Aromatase Inhibitor Therapy	NA	19 (70)
Prior CDK4/6 inhibitor	NA	26 (96)
Number of Prior Therapies – Advanced Breast Cancer, n (%)		
0	41 (100)	0
1	0	18 (67)
2	0	8 (30)
≥3	0	1 (4)
Measurable Baseline Disease, n (%)		
Yes	38 (93)	27 (100)
No	3 (7)	0
Disease Site Involved, n (%)		
Bone Only	1 (2)	0
Bone	26 (63)	18 (67)
Brain	0	0
Liver	15 (37)	17 (63)
Lung	7 (17)	6 (22)
Lymph Node	12 (29)	2 (7)
Plurial Effusion	4 (10)	2 (7)
Skin	1 (2)	0
Other	35 (85)	21 (78)
Number of Disease Sites Involved, n (%)		
1-3	35 (85)	24 (89)
≥4	6 (15)	3 (11)
PIKCA, n (%)		
Wild-type	33 (78)	15 (56)
Mutant	9 (22)	12 (44)
Unknown/Missing	1 (2)	1 (4)

NA, not applicable; SERD, selective estrogen receptor degrader; SERM, selective estrogen receptor modulator.

REFERENCES

1. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
2. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
3. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
4. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
5. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
6. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
7. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
8. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.
9. Finn RS, et al. *N Engl J Med*. 2015;373:1272–1282.

ACKNOWLEDGEMENTS

- Patients and their families/clinicians for participating in the trial.
- Investigators and their support staff who participated in this work.
- Cellular Inc. for sponsoring the study.

Poster PDF

Scan the QR code below to download a PDF of this poster.



RELATED PUBLICATIONS

Scan the QR codes below to access related publications.



RESULTS

Figure 2. Overall Survival 1L Treatment-Naïve, N=41





Figure 3. Overall Survival 2L/3L CDK4/6i-Treated (N=27)



CONCLUSIONS

- Gedatolisib in combination with palbociclib and ET demonstrated encouraging preliminary efficacy in patients with HR+/HER2-ABC; mPFS was 48.4 months in the treatment-naïve subgroup and 12.9 months in the subgroup previously treated with a CDK4/6i who received gedatolisib on an intermittent schedule. [8,9]
- A subsequent analysis of these patients after additional follow-up showed encouraging OS results that compare favorably to data published for currently available standard-of-care regimens.
 - Median OS for the treatment-naïve subgroup was 77.3 months.
 - Median OS for the 2L/3L CDK4/6i-treated patients who received gedatolisib on an intermittent schedule was 33.9 months.
- Combination therapy was well tolerated with few patients discontinuing treatment due to an adverse event. [6,7]
- These encouraging results support further evaluation of this combination therapy in patients with HR+/HER2- ABC.
 - VICTORIA-3 (NCT05501886), an ongoing randomized Phase 3 study, is evaluating patients who previously received a CDK4/6i.
 - A randomized Phase 3 study evaluating treatment-naïve patients (VICTORIA-2) is currently enrolling.